Whitehead Institute Researchers Engineer Specialized Producer Cells to Mass-Manufacture Potent Gene Editing Delivery Vehicles via Genome-Wide Screening

Researchers at the Whitehead Institute identify genes that boost the production of virus-like particles, solving a major bottleneck in gene therapy delivery.

By: AXL Media

Published: Apr 27, 2026, 6:58 AM EDT

Source: Information for this report was sourced from Whitehead Institute

Addressing the Production Bottleneck in Genetic Medicine

The primary challenge facing the widespread application of gene editing is the safe and efficient delivery of molecular machinery into the correct human cells. Virus-like particles (VLPs) have emerged as a leading solution because they possess the natural ability of viruses to enter cells but contain no viral genetic material, making them a safer alternative for therapeutic use. However, producing these particles at a scale and potency required for clinical treatment remains a significant hurdle. Aditya Raguram, a Valhalla Fellow at the Whitehead Institute, argues that the field has focused too heavily on the architecture of the particles themselves while ignoring the biological factories—the producer cells—that actually assemble them.

A Systematic Search of the Human Genome

To understand how to optimize these cellular factories, the research team conducted a genome-wide search to pinpoint which genes either facilitate or block the assembly of delivery vehicles. By creating a massive pool of producer cells and switching off nearly every gene in the human genome across the population, the scientists were able to observe the resulting impact on production. Each VLP was engineered to carry a genetic tag identifying the specific gene that had been deactivated in its "parent" cell. This innovative tagging system allowed the team to read the molecular output and determine with high precision which genetic deletions boosted production and which ones hindered it.

Disabling the Genetic Brakes on Guide RNA

The study identified a standout gene that serves as a natural brake on the cell's production of guide RNAs, which are the essential components that direct gene editors to their targets. When the researchers disabled this specific gene, the producer cells began generating a significantly higher volume of guide RNAs, ensuring that each delivery particle was packed with more functional cargo. This improvement was not limited to a single type of gene editor; the team tested the modified producer cells across five different delivery systems and multiple cargo types, finding that the engineered cells consistently produced more potent and effective vehicles for gene therapy.